Last reviewed · How we verify
A Prospective, Multicenter Clinical Trial Exploring the Optimal Combination Strategies of Radiotherapy and Immunotherapy for Advanced Triple-Negative Breast Cancer
This study aims to explore the best combination patterns of radiotherapy and immunotherapy for advanced triple-negative breast cancer (TNBC).
Details
| Lead sponsor | Sun Yat-sen University |
|---|---|
| Phase | Phase 2 |
| Status | RECRUITING |
| Enrolment | 60 |
| Start date | 2024-12-20 |
| Completion | 2027-01 |
Conditions
- Triple-Negative Breast Cancer (TNBC)
Interventions
- radiotherapy 5 Gy × 5 fractions, once a day
- radiotherapy 8 Gy × 5 fractions, once a day
- radiotherapy 8 Gy × 3 fractions, once every other day
- radiotherapy 10 Gy× 3 fractions, once every other day
- radiotehrapy 0.5Gy twice-a-day × 2 days, repeat for 4 cycles (total 8Gy)
- Toripalimab
- chemotherapy regimen selected by the investigator
Primary outcomes
- Progression-free survival at 6 months (6m-PFS rate) — 6 months
Progression-free survival at 6 months (6m-PFS rate) is defined as the percentage of patients who have not experienced disease progression or death due to any cause at the 6-month mark after starting treatment.
Countries
China